U.K. Pharmaceuticals & Biotech Strong Balance Sheet Stocks

Physiomics

Market Cap: UK£1.2m

Provides consulting services to pharmaceutical companies in the areas of outsourced quantitative pharmacology and computational biology in the United Kingdom, the United States, and the European Union Switzerland.

Fusion Antibodies

Market Cap: UK£6.9m

A contract research organization, engages in the research, development, and manufacture of recombinant proteins and antibodies primarily for cancer and infectious diseases in the United Kingdom, the rest of Europe, North America, and internationally.

IXICO

Market Cap: UK£7.3m

Provides data analytics services to the biopharmaceutical industry in the United Kingdom, Switzerland, the Netherlands, Ireland, rest of Europe, and the United States.

Animalcare Group

Market Cap: UK£146.9m

Develops, sells, and distributes licensed veterinary pharmaceuticals and identification products, and services for companion and production animals, and equine veterinary markets in Europe and internationally.

BSF Enterprise

Market Cap: UK£1.7m

Develops and commercializes cutting-edge tissue-engineered solutions.

Oxford Nanopore Technologies

Market Cap: UK£1.1b

Engages in the research, development, manufacture, and commercialization of a nanopore based sequencing platform that allows the real-time analysis of deoxyribonucleic acid (DNA) or ribonucleic acid (RNA) in the Americas, Europe, the Middle East, Africa, India, and the Asia Pacific.

Theracryf

Market Cap: UK£4.8m

A clinical stage therapeutics company, engages in the development of therapeutics for oncology and behavioral brain disorders.

hVIVO

Market Cap: UK£109.7m

Operates as a pharmaceutical service and contract research company in the United Kingdom.

Diaceutics

Market Cap: UK£95.1m

A diagnostic commercialisation company, provides data, data analytics, and implementation services for pharmaceutical companies worldwide.

ECO Animal Health Group

Market Cap: UK£35.6m

Develops, registers, and markets pharmaceutical products for animals worldwide.

Bioventix

Market Cap: UK£127.9m

Bioventix PLC creates, manufactures, and supplies sheep monoclonal antibodies (SMAs) for diagnostic applications worldwide.

genedrive

Market Cap: UK£9.4m

Engages in the design, development, and manufacture of molecular diagnostics testing equipment for use in genotyping, pathogen detection, infectious disease detection, and other clinical indications.

OptiBiotix Health

Market Cap: UK£15.7m

A life sciences company, engages in the discovery and development of microbiome modulators in the United Kingdom, the United States, China, and internationally.

Sareum Holdings

Market Cap: UK£23.4m

A clinical stage small molecule drug development company, engages in the discovery and development of therapeutic drugs for cancer and autoimmune diseases.

SkinBioTherapeutics

Market Cap: UK£44.8m

A life science company, engages in research and development, and commercialization of technology that harnesses the microbiome for human health in the United Kingdom, the United States, Europe, and internationally.

Oxford BioDynamics

Market Cap: UK£8.8m

Operates as a biotechnology company that discovers and develops biomarkers for use in the pharmaceutical and biotechnology industry primarily in the United States and the United Kingdom.

MaxCyte

Market Cap: UK£202.0m

A life sciences company, discovers, develops, and commercializes cell therapeutics in the United States and internationally.

Nuformix

Market Cap: UK£1.8m

Together with its subsidiary, Nuformix Technologies Limited, operates in the field of pharmaceutical development for treating fibrosis and oncology through drug repurposing in the United Kingdom.

N4 Pharma

Market Cap: UK£2.0m

A specialist pharmaceutical company, develops silica nanoparticle delivery systems to enhance the cellular delivery of cancer treatments, gene therapy, and vaccines in the United Kingdom.

Cizzle Biotechnology Holdings

Market Cap: UK£6.1m

Develops an immunoassay test for the CIZ1B cancer biomarker for the early detection of lung cancer in the United Kingdom.

Verici Dx

Market Cap: UK£4.9m

Develops prognostic and diagnostic tests for kidney transplant patients.

Hikma Pharmaceuticals

Market Cap: UK£4.0b

Develops, manufactures, markets, and sells a range of generic, branded, and in-licensed pharmaceutical products.

Poolbeg Pharma

Market Cap: UK£13.5m

Operates as a biopharmaceutical company, engages in the development and commercialization of medicines for unmet medical needs in the United Kingdom.

Oxford Biomedica

Market Cap: UK£295.7m

A contract development and manufacturing organization, focuses on delivering therapies to patients worldwide.

Alliance Pharma

Market Cap: UK£347.6m

A holding company, acquires, markets, and distributes consumer healthcare products and prescription medicines in Europe, the Middle East, Africa, the Asia Pacific, China, and the Americas.

Arecor Therapeutics

Market Cap: UK£14.3m

A biopharmaceutical company, focuses on developing products in diabetes and other indications ion the United Kingdom.

Aptamer Group

Market Cap: UK£5.2m

Provides binders for research, diagnostics, and therapeutics in the United Kingdom, rest of Europe, the United States, and internationally.

Incanthera

Market Cap: UK£7.3m

A dermatology and oncology therapeutics company, focuses on the dermatological formulation and delivery technologies for various indications.

ValiRx

Market Cap: UK£2.0m

A biopharmaceutical company, engages in the development of oncology therapeutics and companion diagnostics in the United Kingdom.

Futura Medical

Market Cap: UK£30.1m

Research, develops, and sells pharmaceutical and healthcare products for sexual health.

LungLife AI

Market Cap: UK£275.9k

A diagnostic company, researches and develops clinical diagnostic solutions for lung cancer with artificial intelligence (AI) technology in the United States and the People’s Republic of China.

ProBiotix Health

Market Cap: UK£13.4m

Develops probiotics to tackle cardiovascular disease and other lifestyle conditions in the United Kingdom, the United States, and internationally.

Genflow Biosciences

Market Cap: UK£3.7m

Operates as a biotechnology company that focuses on developing biological interventions aimed at tackling the effects of ageing, slowing, and halting the ageing process, and reducing the incidence of age-related diseases with increase in health span in the United Kingdom and Belgium.

Kanabo Group

Market Cap: UK£1.6m

A digital health company, engages in the research, development and commercialization of cannabis-derived formulations and therapeutic inhalation devices.

ImmuPharma

Market Cap: UK£10.7m

A biopharmaceutical company, discovers and develops peptide-based therapeutics in the United Kingdom.